Aripiprazole lauroxil

Description

Aripiprazole lauroxil · CAS 1259305-29-7 · C36H51Cl2N3O4. UNII B786J7A343. Melting Point: 81-83; Solubility: <0.01 mg/mL; LogP: 5.3.

Identification

CAS Registry Number	1259305-29-7
PubChem CID	49831411
Molecular formula	C36H51Cl2N3O4
IUPAC name	[7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-2-oxo-3,4-dihydroquinolin-1-yl]methyl dodecanoate
UNII (FDA)	B786J7A343

Computed Descriptors

Molecular Weight	660.7
XLogP3	10
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	20
Exact Mass	659.3256625
Monoisotopic Mass	659.3256625
Topological Polar Surface Area	62.3
Heavy Atom Count	45
Formal Charge	0

Physical & Chemical Properties

Melting Point	81-83
Solubility	<0.01 mg/mL
LogP	5.3

Physical description & handling notes

• Aripiprazole, which is a major pharmacological metabolite of aripiprazole lauroxil, serves to improve the positive and negative symptoms of schizophrenia by modulating dopaminergic signalling pathways. Aripiprazole lauroxil is reported to have minimal effects on sexual function or prolactin levels.

GHS Hazard Classification

Reported hazard statements	H302 (100%), H312 (50%), H332 (50%), H372 (50%), H412 (50%), H413 (50%)

Documented Uses

• Aripiprazole lauroxil is indicated for the treatment of schizophrenia and related psychotic disorders.
• SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
• Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.
• Following a single extended-release intramuscular injection of aripiprazole lauroxil, aripiprazole can be detected in the systemic circulation from 5 to 6 days and is continued to be released for an additional 36 days. The concentrations of aripiprazole increases with consecutive doses of aripiprazole lauroxil and the steady state is reached following the fourth monthly injection. The systemic exposure to aripiprazole was similar when comparing deltoid and gluteal intramuscular injections.
• Based on the pharmacokinetic study for aripiprazole, less than 1% of unchanged aripiprazole was excreted in the urine and approximately 18% of the oral dose was recovered unchanged in the feces.
• Based on population pharmacokinetic analysis, the apparent volume of distribution of aripiprazole following intramuscular injection of aripiprazole lauroxil was 268 L, indicating extensive extravascular distribution following absorption. Health human volunteer study indicates that aripiprazole crosses the blood-brain barrier.

Synonyms

Aripiprazole lauroxil; 1259305-29-7; Aristada; RDC-3317; ALKS 9072; Aristada initio; ALKS 9070; RDC 3317; ALKS-9070; ALKS-9072; RDC3317; B786J7A343; CHEBI:90930; DTXSID60154997; (7-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)methyl dodecanoate; [7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-2-oxo-3,4-dihydroquinolin-1(2H)-yl]methyl dodecanoate

Frequently Asked Questions

What are the CAS number and molecular formula of Aripiprazole lauroxil?

CAS 1259305-29-7; molecular formula C36H51Cl2N3O4; molecular weight — g/mol.

What other names is Aripiprazole lauroxil known by?

Aripiprazole lauroxil, 1259305-29-7, Aristada, RDC-3317, ALKS 9072, Aristada initio.

Is Aripiprazole lauroxil classified as hazardous?

Hazard statements reported: H302, H312, H332, H372, H412.

What are the key physical properties of Aripiprazole lauroxil?

Melting Point: 81-83; Solubility: <0.01 mg/mL; LogP: 5.3.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.